全文获取类型
收费全文 | 517286篇 |
免费 | 38201篇 |
国内免费 | 11139篇 |
专业分类
耳鼻咽喉 | 6241篇 |
儿科学 | 9903篇 |
妇产科学 | 11556篇 |
基础医学 | 73836篇 |
口腔科学 | 14145篇 |
临床医学 | 46976篇 |
内科学 | 97440篇 |
皮肤病学 | 10021篇 |
神经病学 | 33899篇 |
特种医学 | 18647篇 |
外国民族医学 | 147篇 |
外科学 | 73620篇 |
综合类 | 33044篇 |
现状与发展 | 30篇 |
一般理论 | 76篇 |
预防医学 | 27316篇 |
眼科学 | 12794篇 |
药学 | 47196篇 |
122篇 | |
中国医学 | 9966篇 |
肿瘤学 | 39651篇 |
出版年
2023年 | 2882篇 |
2022年 | 6885篇 |
2021年 | 9763篇 |
2020年 | 6896篇 |
2019年 | 7365篇 |
2018年 | 9335篇 |
2017年 | 7893篇 |
2016年 | 7752篇 |
2015年 | 10206篇 |
2014年 | 13301篇 |
2013年 | 14781篇 |
2012年 | 20373篇 |
2011年 | 21215篇 |
2010年 | 13971篇 |
2009年 | 12121篇 |
2008年 | 16927篇 |
2007年 | 17752篇 |
2006年 | 17013篇 |
2005年 | 15477篇 |
2004年 | 13578篇 |
2003年 | 13252篇 |
2002年 | 12183篇 |
2001年 | 31320篇 |
2000年 | 31351篇 |
1999年 | 25999篇 |
1998年 | 6718篇 |
1997年 | 5974篇 |
1996年 | 5046篇 |
1995年 | 4641篇 |
1994年 | 4161篇 |
1993年 | 3576篇 |
1992年 | 16896篇 |
1991年 | 15580篇 |
1990年 | 14853篇 |
1989年 | 14594篇 |
1988年 | 13141篇 |
1987年 | 12521篇 |
1986年 | 11539篇 |
1985年 | 10689篇 |
1984年 | 7233篇 |
1983年 | 5862篇 |
1982年 | 2963篇 |
1979年 | 5650篇 |
1978年 | 3529篇 |
1977年 | 3172篇 |
1975年 | 2755篇 |
1974年 | 3216篇 |
1973年 | 2992篇 |
1972年 | 2931篇 |
1971年 | 2895篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
111.
112.
Wen Wang Yanmei Liu Chuan Yu Jing Tan Weiyi Xiong Duo Dong 《Expert opinion on drug safety》2020,19(3):339-347
ABSTRACTObjectives: Limited evidence has suggested that cefoperazone-sulbactam causes coagulation disorders and bleeding.Methods: The authors conducted a retrospective study to compare patients receiving cefoperazone-sulbactam versus those treated with cefoperazone-tazobactam or ceftazidime. Propensity-score matching was used to explore whether treatment with cefoperazone-sulbactam increased the risk of prothrombin time (PT) prolongation, coagulation disorders, and bleeding, or decreased platelets (PLT).Results: The cohort included 23,242 patients. Among patients receiving cefoperazone-sulbactam, the risk of PT prolongation, coagulation disorders, decreased PLT, and bleeding was 5.3%, 9.2%, 15.7%, and 4.2%, respectively. Propensity-score matching analyses suggested that cefoperazone-sulbactam increased the risk of PT prolongation (aOR 2.26, 95% CI 1.61–3.18), coagulation disorders (aOR 1.81, 95% CI 1.43–2.30), and decreased PLT (aOR 1.46, 95% CI 1.25–1.72), but not increase bleeding (aOR 1.05, 95% CI 0.79–1.40) compared with ceftazidime. Patients receiving cefoperazone-sulbactam had higher risk of PT prolongation (aOR 1.53, 95% CI 1.11–2.10), coagulation disorders (aOR 1.53, 95% CI 1.21–1.95), but not decreased PLT (aOR 0.93, 95% CI 0.81–1.07) or bleeding (aOR 1.11, 95% CI 0.87–1.42), compared with those receiving cefoperazone-tazobactam.Conclusion: Cefoperazone-sulbactam may be associated with a higher risk of PT prolongation and coagulation disorders compared with cefoperazone-tazobactam and ceftazidime. 相似文献
113.
114.
Amy Y. Zhang Christopher Burant Alex Z. Fu Gerald Strauss Donald R. Bodner Lee Ponsky 《Journal of psychosocial oncology》2020,38(2):210-227
AbstractPurpose: We examined underlying psychosocial processes of a behavioral treatment for urinary incontinence (UI) of prostate cancer survivors.Design: Secondary analysis of data collected from a clinical trial.Sample: Two hundred forty-four prostate cancer survivors who participated in a clinical trial of behavioral intervention to UI as intervention or control subjects.Methods: The participants had a 3-month behavioral intervention or usual care and were followed up for an additional 3?months. They were assessed at baseline, 3, and 6?months. Latent growth curve models were performed to examine trajectories of each study variable and relationships among the variables.Findings: Increasing self-efficacy and social support were significantly and independently associated with more reduction of urinary leakage frequency over time.Implications for psychosocial oncology: Providing problem-solving skills and social support, including peer support, are essential for empowering patients to reduce UI. 相似文献
115.
116.
Prevalence of Potentially Inappropriate Prescribing Among Hong Kong Older Adults: A Comparison of the Beers 2003, Beers 2012, and Screening Tool of Older Person's Prescriptions and Screening Tool to Alert doctors to Right Treatment Criteria 下载免费PDF全文
117.
118.
119.
Retreatment in patients with psoriasis achieving response with etanercept after relapse due to treatment interruption: results from the CRYSTEL study 下载免费PDF全文
120.